Pathophysiology and biochemistry of dyskinesia: Clues for the development of non-dopaminergic treatments

Journal of Neurology, Supplement

Volumn 247, Issue 2, 2000, Pages 43-50

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine receptors; Dyskinesia; Levodopa; Non dopaminergic therapies; Striatal output pathways

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MESSENGER RNA; MUSCARINIC RECEPTOR; NEUROPEPTIDE;

CONFERENCE PAPER; CORPUS STRIATUM; DYSKINESIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; BRAIN; DYSKINESIAS; HUMANS; PARKINSON DISEASE;

EID: 0034102025     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949-956
2. Banerji T, Pearce RKB, Jackson MJ, Jenner P, Marsden CD (1996) Cholinergic manipulation of L-dopa-induced dyskinesias in the MPTP-treated common marmoset (Callithrix jacchus). Br J Pharmacol 117 [Suppl] :24 (abstract)
3. 3H]spiperone binding. Brain Res 379: 294-299
4. Bedard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Di Paolo T (1992) Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey tell us? Can J Neurol Sci 19: 134-137
5. Bedard PJ, Gomez-Mancilla B, Blanchet P, Gagnon C, Falardeau P, Di Paolo T (1993) Role of selective D-1 and D-2 agonists in inducing dyskinesia in drugnaive MPTP monkeys. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno U (eds) Advances in neurology, vol 60. Raven Press, New York, pp 113-118
6. Bedard PJ, Gomez-Mancilla B, Blanchet P, Calon F, Grondin R, Gagnon C, Falardeau P, Goulet M, Morissette M, Rouillard C, Di Paolo T (1997) Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, volume 2. Wells Medical, Royal Tunbridge Wells, pp 101-113
7. Blanchet P, Bedard PJ, Britton DR, Kebabian JW (1993) Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 267 : 275-279
8. Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walter RR, Piercey MF (1995) Continuous administration decreases and pulsatile administration increases behavioural sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP monkeys. J Pharmacol Exp Ther 272:854-859
9. Blanchet PJ, Crondin R, Bedard PJ (1996) Dyskinesia and wearing-off following dopamine D-1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 11:91-94
10. Blanchet PJ, Konitosiotis S, Chase TN (1998) Amanladine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802
11. Block G, Liss C, Reines S, Irr J, Nibbelink D (1997) Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicentre 5-year study. The CR First Study Group. Eur Neurol 37 : 23-27
12. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by L- dopa in squirrel monkeys. Clin Neuropharmacol 13:448-458
13. Brotchie JM (1998) Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 13:871-876
14. Brown SJ, Gill R, Evenden J, Iversen SD. Richardson PJ (1991) Striatal A2 receptor regulates apomorphine induced turning in rats with unilateral dopamine denervation. Psychopharmacology 103:78-83
15. Calabresi P, Bernardi G (1999) Levodopa-induced dyskinesia: a pathological form of synaptic plasticity at corticostriatal synapses? Ann Neurol (in press)
16. Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bedard PJ, Di Paolo T (1995) Levodopa or D-2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA receptors in the striatopallidal complex. Brain Res 680: 43-52
17. Cenci MA, Lee CS, Björklund A (1998) L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706
18. Chase TN, Holden EM, Brody JA (1973) Levodopa-induced dyskinesia: comparison in parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol 29: 328-330
19. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374-379
20. Di Chiara G, Morelli M, Console S (1994) Modulatory functions of neurotransmitters in the striatum: Ah/dopamine/NMDA interactions. Trends Neurosci 17: 228-233
21. Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor messenger-RNAs in the rat. Br J Pharmacol 118: 1461-1468
22. Falardeau P, Bedard PJ, Di Paolo T (1988) Relation between brain dopamine loss and D-2 dopamine receptor density in MPTP monkeys. Neurosci Lett 86:225-229
23. Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T (1988) Behavioural and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 150:59-66
24. Gagnon C, Bedard PJ, Di Paolo (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 178: 115-120
25. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in GDNF-treated parkinsonian monkeys. Nature 380: 252-255
26. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma JF Jr (1990) D-1 and D-2 dopamine-receptor regulated gene expression of striato-GPi/nigral and striatopallidal neurons. Science 250: 1429-1432
27. Gerfen CR, McGinty JF, Young SW III (1991). Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 11: 1016-1031
28. Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD (1993) Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 14: 184-194
29. Gomez-Mancilla B, Bedard PJ (1991) Effect of D-1 and D-2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259:409-413
30. Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemiparkinsonism reveal dopamine D-2 but not D-1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 514: 103-110
31. Herrero M-T, Levy R, Ruberg M, Luquin MR, Villares J, Guilleri J, Faucheux B, Javoy-Agid F, Guridi J, Agid Y, Obeso JA, Hirsch EC (1996) Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47 : 219-224
32. Iravani MN, Costa S, Jackson MJ, Jenner P, Marsden CD (1999) Reduction of L-dopa induced dyskinesias following intraventricular administration of GCNF in common marmosets. Br J Pharmacol 126 [Suppl]:P232 (abstract)
33. Jankovic J, Marsden CD (1993) Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Williams & Wilkins, Baltimore, pp 115-144
34. Jenner P, Marsden CD (1982) Antiparkinsonian and antidyskinetic drugs. In: Tyrer PJ (ed) Drugs in psychiatric practice. Butterworths, London, pp 82-125
35. Jolkkonen J, Jenner P, Marsden CD (1995) L-dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res 32 : 297-307
36. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM (1985) Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 382: 360-364
37. Kanda T, Shiozaki S, Schimada J, Suzuki F, Nakamura J (1994) KF17387: a novel selective adenosine A2a receptor antagonist with anticataleptic activity. Eur J Pharmacol 256: 263-268
38. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC (1995) Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 18 : 527-535
39. Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P (1998) Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
40. Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P (1999) Combined use of the adenosine A2a antagonist KW6002 with L-DOPA or with selective D-1 or D-2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP treated monkeys. Exp Neurol (in press)
41. Koller WC (1994) Adverse effects of levodopa and other symptomatic therapies: impact on quality of life of the Parkinson's disease patient. In: Stern MB (ed) Beyond the decade of the brain, volume 1. Wells Medical. Royal Tunbridge Wells, pp 31-45
42. Kurokawa M, Kirk IP, Kirkpatrick A, Kase H, Richardson PJ (1994) Inhibition by KF17837 of adenosine A2a receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 113:43-48
43. Lang AE (1989) Drug treatment of dystonia. In: Quinn NP, Jenner PJ (eds) Disorders of movement. Academic Press, London, pp 313-321
44. 67 mRNA. Eur J Neurosci 7: 1199-1209
45. Lindsay RM, Altar CA, Cedarbaum JM, Hyman C, Wiegand SJ (1993) The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp Neurol 124: 103-118
46. Martinez-Mir MI, Probst A, Palacios JM (1991) Adenosine A2a receptors: selective localisation in the human basal ganglia and alterations with disease. Neuroscience 42:697-706
47. Mena I, Court J, Fuenzalida PS, Papavasiliou PS, Gellene R (1970) Modification of chronic manganese poisoning: treatment with levodopa or 5-OH tryptophan. N Engl J Med 282:5-9
48. Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR (1990) Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 5 : 49-54
49. Mones RJ (1972) Levodopa-induced dyskinesia in the normal rhesus monkey. Mt Sinai J Med 39 : 197-201
50. Mones RJ (1973) Experimental dyskinesias in normal rhesus monkey. In: Barbeau A, Chase TN, Paulson GW (eds) Advances in neurology, vol 1. Raven Press, New York, pp 665-669
51. Mones RJ, Elizan TS, Seigel GJ (1971) Analysis of L-DOPA induced dyskinesia in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 34: 668-673
52. Mones RJ, Pasik P, Pasik T, Wilks S (1973) The modification of L-dopa-induced dyskinesia in the monkey by unilateral nigral lesions. Trans Am Neurol Assoc 98: 234-237
53. Montastruc JL, Rascol O, Rascol A (1981) A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a three-year follow-up. J Neurol Neurosurg Psychiatry 44: 1021-1023
54. Mori A, Shindou T, Ichimura M, Nonaka H, Kase H (1996) The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurones. J Neurosci 16:605-611
55. Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bedard PJ, Di Paolo T (1996) Changes of D-1 and D-2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetruhydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol Pharmacol 50: 1073-1079
56. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, Di Paolo T (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D-2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res Mol Brain Res 49:55-62
57. Nutt JG (1990) Levodopa-induced dyskinesia: review, observations and speculations. Neurology 40:340-345
58. Nutt JG, Holford NHG (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39 : 561-573
59. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM (1989) Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39(suppl 2): 11-19
60. Obeso JA, Grandas F, Herrero MT, Horowski R (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 6:889-897
61. Obeso JA, Linazasoro G, Gorospe A, Rodriguez C, Lera G (1997) Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, volume 2. Wells Medical, Royal Tunbridge Wells, pp 11-35
62. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloff L, Kopin IJ (1990) Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 10: 860-869
63. Papa SM, Chase TN (1996) Levodopa-induced dyskinesia improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39 : 574-578
64. Parkes D, Jenner P, Rushton D, Marsden D (1987) Neurological disorders. Springer Verlag, London
65. Paulson GW (1973) Dyskinesias in monkeys. In: Barbeau A, Chase TN, Paulson GW. (eds) Advances in neurology, vol 1. Raven Press, New York, pp 647-650
66. Pearce RKB, Banerji T, Jenner P, Marsden CD (1998) De Novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13 : 234-241
67. Pearce RKB, Heikkila M, Linden I-B, Jenner P, Marsden CD (1999) L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Brain (in press)
68. Pearce RKB, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD (1999) Actions of the D-1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopaprimed common marmosets. Psychopharmacology 142 : 51-60
69. Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 10 : 731-740
70. Pearce RKB, Zeng B-Y, Jenner P, Marsden CD (1995) Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic L- dopa administration. Br J Pharmacol 116 [Suppl] : 78 (abstract)
71. Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Avid F, Ruberg M, Agid Y (1988) D-1 and D-2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 86: 291-306
72. 3H]SCH 23390 labeled D-1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 114: 235-237
73. 3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113:467-468
74. Rajput AH, Fenton ME, Birdi S, Macaulay R (1997) Is levodopa toxic to human substantia nigra? Mov Disord 12:634-638
75. Rascol O (1997) Ropinirole: clinical profile. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, volume 2. Wells Medical, Royal Tunbridge Wells, pp 163-175
76. Riley DE (1997) Lack of dyskinesias or parkinsonism after long-term exposure to levodopa. Mov Disord 12 (suppl 1) : P3222
77. Rinne JO, Rinne JK, Laakso K, Lonnberg P, Rinne UK (1985) Dopamine D-1 receptors in the parkinsonian brain. Brain Res 359:306-310
78. Rinne UK (1986) Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 45 : 519-523
79. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A (1997) Autoradiographic distribution of Ml, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 26 : 341-350
80. 3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 49: 1449-1454
81. Sassin JF (1975) Drug-induced dyskinesia in monkeys. In: Meldrum BS, Marsden CD (eds) Advances in neurology, vol 10. Raven Press, New York, pp 47-54
82. Sassin J, Taub S, Weitzman E. (1971) Abnormal behaviour patterns produced in normal monkeys by L-dopa. Neurology 21 : 403
83. Sassin JF, Taub S, Weitzman ED (1972) Hyperkinesia and changes in behaviour produced in normal monkeys by L-dopa. Neurology 22 : 1122-1125
84. Schneider JS (1989) Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 34: 193-196
85. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd K (1998) Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behaviour in parkinsonian monkeys. Mov Disord 13: 637-642
86. Seeman P, Bzowej NH, Guan HC (1987) Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1 : 5-15
87. Tel BC, Zeng B-Y, Pearce RKB, Jenner P, Marsden CD (1998) Changes in striatal preproenkephalin A (PPE-A) and preprotachykinin (PPT) mRNA expression: The effects of L-dopa, bromocriptine and ropinirole in MPTP treated primates. Neurology 50:S4: 3013
88. Tolosa E, Marin C (1997) Dopamine agonists in Parkinson's disease: a clinical review. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, volume 2.: Wells Medical, Royal Tunbridge Wells, pp 143-161
89. Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D-1 and D-2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49 : 717-723
90. Vila M, Levy R, Herrero M-T, Faucheux B, Obeso JA, Agid Y, Hirsch EC (1996) Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. Neuroscience 71 : 903-912
91. Woolf NJ, Butcher LL (1986) Cholinergic systems of the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia and basal forebrain. Brain Res Bull 16 : 603-637
92. Zeng B-Y, Jolkkonen J, Jenner P, Marsden CD (1995) Chronic L-dopa treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 66: 19-28
93. Zeng B-Y, Pearce RKB, MacKenzie GM, Jenner P (1999) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci (in press)
94. Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM (1997) Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282 : 1396-1401